TITLE

The Success Rate of Fibrinolytic Therapy in Fresh and Old Thrombosis of the Iliac and Femoral Veins

AUTHOR(S)
Theiss, Wolfram; Wirtzfeld, Alexander; Fink, Ulrich; Maubach, Peter
PUB. DATE
January 1983
SOURCE
Angiology;Jan1983, Vol. 34 Issue 1, p61
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Since it is still a wide-held belief that fibrinolytic therapy can clear thrombi from deep veins only while they are fresh, we retrospectively analyzed the phlebographic results obtained in 85 patients with thrombosis of the iliac and/or femoral veins with symptoms present for 1 day to 8 weeks prior to treatment. Streptokinase, urokinase, or both drugs successively were administered in these patients for a mean of 9 days (range: 2 to 26 days). Complete or partial resolution of the thrombotic occlusion was obtained in 94%, 82%, and 69%, respectively, in those patients who presented within 3 days, 1 to 2 weeks, and 3 to 4 weeks after the first appearance of symptoms. With a delay of 5 to 8 weeks the results were uniformly poor with only 1 partial recanalization in 7 patients.
ACCESSION #
16438485

 

Related Articles

  • Impotance of Phasicity in Detection of Proximal Iliac Vein Thrombosis with Venous Duplex Examination. Sanford, Deborah A.; Kelly, Donna; Rhee, Soo J.; Stoughton, Julianne; Cantelmo, Nancy L. // Journal for Vascular Ultrasound;Sep2011, Vol. 35 Issue 3, p150 

    Superficial venous reflux is commonly the cause of symptomatic venous disease, but proximal venous obstruction may also play a role. A duplex ultrasound evaluating bilateral common femoral veins can detect differences in phasicity, which may be due to pelvic venous obstruction. We report a case...

  • Axillary Vein Thrombosis. Collier, Paul E.; Diamond, Daniel L.; Young, Joseph C. // Vascular Surgery;May/Jun1984, Vol. 18 Issue 3, p174 

    Three patients with venographically proven axillary vein thromboses were treated with low-dose streptokinase infused directly into the involved vein. These veins had been occluded from twelve hours to three weeks. No complications and no marked systemic effects occurred. Patency was achieved in...

  • Streptokinase : A novel clot buster. Vaishnavi, B.; Mohanasrinivasan, V.; Subathra Devi, C. // Journal of Pharmacy Research;Oct2011, Vol. 4 Issue 10, p3784 

    The leading cause of death in the world is coronary heart diseases. About 7.1 million deaths were attributed to ischemic heart disease in 2001 out of which 80% were in relatively poor countries. According to World Health Organisation (WHO) cardiovascular disease caused over 18 million deaths in...

  • THROMBOLYTIC THERAPY: DIFFERENCES BETWEEN STREPTOKINASE AND UROKINASE. Bell, William R. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p378 

    Compares the relative potency of streptokinase and urokinase as agents for thrombolytic therapy in patients with pulmonary emboli. Therapeutic regimens of streptokinase and urokinase; Biochemical properties of streptokinase and urokinase; Assessment of the therapeutic improvement after the...

  • DISCUSSION. Perler, Bruce // Vascular Surgery;Jan/Feb2000, Vol. 34 Issue 1, p23 

    Focuses on the management of primary axillosubclavian venous thrombosis. Medical comorbidity experienced by patients with secondary upper extremity venous thrombosis; Use of surgical thrombectomy to prevent recurrent venous thrombosis; Safety and efficacy of urokinase compared to streptokinase...

  • Streptase.  // Royal Society of Medicine: Medicines;2002, p511 

    This article presents information on Streptase, a streptokinase preparation. Streptase is a proprietary, prescription-only preparation of the fibrinolytic drug streptokinase. It can be used to treat thrombosis and embolism, and is available in a form for injection.

  • COMBINED THROMBECTOMY AND ISOLATED LIMB PERFUSION WITH STREPTOKINASE IN THE TREATMENT OF DEEP VENOUS THROMBOSIS. Nachbur, Bernard // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p395 

    A new mode of treatment for extensive acute and subacute deep venous thrombosis of the lower extremities combines the beneficial effects of surgical thrombectomy and of thrombolysis with streptokinase during the course of a single surgical intervention. Rapid-flow regional perfusion is the...

  • A Bi-Functional Anti-Thrombosis Protein Containing Both Direct-Acting Fibrin(ogen)olytic and Plasminogen-Activating Activities. Hailong Yang; Yipeng Wang; Yao Xiao; Ying Wang; Jing Wu; Cunbao Liu; Huahu Ye; Fengliang Li; Haining Yu; Lai, Ren // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Direct-acting fibrin(ogen)olytic agents such as plasmin have been proved to contain effective and safety thrombolytic potential. Unfortunately, plasmin is ineffective when administered by the intravenous route because it was neutralized by plasma antiplasmin. Direct-acting fibrin(ogen)olytic...

  • Bilateral Deep Femoral Vein Thrombosis. Ratanaprasatporn, Linda; Gonsalves, Gail; Garcia-Toca, Manuel; Slaiby, Jeffrey M.; Marcaccio, Edward J.; Tec Chong // Journal for Vascular Ultrasound;Dec2012, Vol. 36 Issue 4, p274 

    Introduction.--Deep vein thrombosis (DVT) is a major national health problem, especially among the critically ill and elderly. Most clinically significant DVTs involve the proximal veins of the lower limb, particularly the iliac, common femoral, femoral, and popliteal veins. Case Study.--We...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics